Key result
Higher SPISE index is linked to ~31% lower incident CVD risk vs lowest tertile.
Why the study?
Does a higher SPISE index predict a lower risk of incident CVD and CHD in participants with early-stage CKM syndrome?
Cohort (n=391,793)
Yes
Does a higher SPISE index predict a lower risk of incident CVD and CHD in participants with early-stage CKM syndrome?
Hazard Ratio: 0.69 (95% CI 0.67–0.7)
The SPISE index, a simple noninvasive surrogate for insulin sensitivity, is independently associated with a lower risk of incident CVD and CHD in early-stage CKM syndrome, highlighting its potential utility for cardiovascular risk stratification.
Background Insulin resistance is a core metabolic abnormality driving the progression of cardiovascular-kidney-metabolic (CKM) syndrome. However, the gold-standard hyperinsulinemia-euglycemic clamp remains challenging for routine clinical use. The Single-Point Insulin Sensitivity Estimator (SPISE) index, calculated from HDL-C, triglycerides, and BMI without requiring insulin measurement, offers a simple and noninvasive alternative. However, its prognostic value for incident cardiovascular disease (CVD) in early-stage CKM syndrome (stages 0–3) has not been established. Methods This prospective cohort study included 391,793 participants from the UK Biobank with CKM stage 0–3. Participants were followed for a median of 7.6 years. Cox proportional hazards regression, and restricted cubic spline regression analyses were employed to examine the association between SPISE and incident CVD and coronary heart disease (CHD), adjusting for demographic, lifestyle, and clinical covariates. Subgroup analyses and sensitivity analyses were also conducted. Results During follow-up, 66,577 participants (17%) with stage 0–3 CKM syndrome experienced incident CVD, including 31,597 cases (8%) of CHD. SPISE demonstrated a significant L-shaped, inverse association with CVD risk, with an inflection point at 5.81 (P for nonlinearity < 0.001).Compared with the lowest tertile, the second and highest tertiles of SPISE were associated with 21% (HR 0.79, 95% CI 0.77–0.80) and 31% (HR 0.69, 95% CI 0.67–0.70) lower risk of incident CVD, respectively. The protective association was stronger for CHD, with corresponding HRs of 0.73 (95% CI 0.71–0.75) and 0.54 (95% CI 0.52–0.55). Subgroup analyses revealed more pronounced benefits among younger participants (< 45 years; HR 0.71, 95% CI 0.68–0.74 for CVD) and never/previous smokers (P for interaction < 0.005). Conclusion In this large population-based study, higher SPISE index was independently and nonlinearly associated with lower risk of incident CVD and CHD in patients with early-stage CKM syndrome. The SPISE index may serve as a practical, cost-effective tool for cardiovascular risk stratification and early prevention in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) conducted a cohort in Early-stage cardiovascular-kidney-metabolic (CKM) syndrome (n=391,793). Single-Point Insulin Sensitivity Estimator (SPISE) index vs. Lowest tertile of SPISE index was evaluated on Incident cardiovascular disease (CVD) (HR 0.69, 95% CI 0.67-0.70). A higher SPISE index was associated with a lower risk of incident cardiovascular disease, with the highest tertile showing a 31% lower risk compared to the lowest (HR 0.69; 95% CI 0.67-0.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: